Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease: Primary Clinical Results of the ACADEMIC Study
暂无分享,去创建一个
B. Horne | J. Carlquist | R. Pearson | Jeffrey L. Anderson | T. Bunch | J. Muhlestein | A. Allen | S. Trehan | Jeffrey L. Anderson | K. Salunkhe | Cindy Nielson
[1] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[2] B. Horne,et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. , 1999, Circulation.
[3] P. Libby,et al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. , 1999, The Journal of clinical investigation.
[4] E. Gurfinkel,et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. , 1999, European heart journal.
[5] G. Byrne,et al. A Chlamydia pneumoniae Component That Induces Macrophage Foam Cell Formation Is Chlamydial Lipopolysaccharide , 1998, Infection and Immunity.
[6] P. Libby,et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. , 1998, Circulation.
[7] B. Horne,et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. , 1998, Journal of the American College of Cardiology.
[8] G. Byrne,et al. Induction of macrophage foam cell formation by Chlamydia pneumoniae. , 1998, The Journal of infectious diseases.
[9] J. Carlquist,et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. , 1998, Circulation.
[10] A. Camm,et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. , 1998, Circulation.
[11] P. Libby,et al. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. , 1997, Circulation.
[12] E. Gurfinkel,et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.
[13] I. Fong,et al. Rabbit model for Chlamydia pneumoniae infection , 1997, Journal of clinical microbiology.
[14] J. Ramírez. Isolation of Chlamydia pneumoniae from the Coronary Artery of a Patient with Coronary Atherosclerosis , 1996, Annals of Internal Medicine.
[15] M L Woods,et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. , 1996, Journal of the American College of Cardiology.
[16] J. Ramirez,et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells , 1996, Infection and immunity.
[17] P. Cannon,et al. Oxidized low density lipoproteins alter macrophage lipid uptake, apoptosis, viability and nitric oxide synthesis. , 1996, The Journal of nutrition.
[18] A. Coulson,et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. , 1995, Circulation.
[19] J. Walsh,et al. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. , 1995, The New England journal of medicine.
[20] Qingbo Xu,et al. Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis. , 1995, International archives of allergy and immunology.
[21] R. Ross,et al. Cell biology of atherosclerosis. , 1995, Annual review of physiology.
[22] M. Debakey,et al. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis , 1994, Journal of medical virology.
[23] A. Becker,et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.
[24] E. Benditt,et al. Chlamydia pneumoniae, strain TWAR and atherosclerosis. , 1993, European heart journal.
[25] H. Fukushi,et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. , 1993, The Journal of infectious diseases.
[26] M. Nieminen,et al. Chlamydia Pneumoniae‐Specific Circulating Immune Complexes in Patients With Chronic Coronary Heart Disease , 1993, Circulation.
[27] N. Holbrook,et al. Vascular heat shock protein expression in response to stress. Endocrine and autonomic regulation of this age-dependent response. , 1993, The Journal of clinical investigation.
[28] Grayston Jt. Infections caused by Chlamydia pneumoniae strain TWAR. , 1992 .
[29] H. Foy,et al. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. , 1992, The Journal of infectious diseases.
[30] D. Patton,et al. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. , 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[31] D. Siscovick,et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. , 1992, JAMA.
[32] M. Leinonen,et al. Chronic Chlamydia pneumoniae Infection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study , 1992, Annals of Internal Medicine.
[33] J. Grayston. Infections caused by Chlamydia pneumoniae strain TWAR. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] K. Chirgwin,et al. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR) , 1989, Antimicrobial Agents and Chemotherapy.
[35] M. Nieminen,et al. SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.
[36] J. Altman,et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. , 1986, The New England journal of medicine.